Fluorogenic or fluorescent reporter molecules and their...

Details Fluorogenic or fluorescent reporter molecules and their... Fluorogenic or fluorescent reporter molecules and their...

2007-09-18

2007-09-18

Gitomer, Ralph (Department: 1657)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Testing efficacy or toxicity of a compound or composition

C424S009600

Reexamination Certificate

active

10829381

ABSTRACT:
The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.

REFERENCES:
patent: 4044126 (1977-08-01), Cook et al.
patent: 4336186 (1982-06-01), Gargiulo et al.
patent: 4364923 (1982-12-01), Cook et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4557862 (1985-12-01), Mangel et al.
patent: 4640893 (1987-02-01), Mangel et al.
patent: 5208148 (1993-05-01), Haugland et al.
patent: 5227487 (1993-07-01), Haugland et al.
patent: 5362628 (1994-11-01), Haugland et al.
patent: 5443986 (1995-08-01), Haughland et al.
patent: 5556992 (1996-09-01), Gaboury et al.
patent: 5576424 (1996-11-01), Mao et al.
patent: 5587490 (1996-12-01), Goodrich, Jr. et al.
patent: 5605809 (1997-02-01), Komoriya et al.
patent: 5698411 (1997-12-01), Lucas et al.
patent: 5714342 (1998-02-01), Komoriya et al.
patent: 5733719 (1998-03-01), Jaffe et al.
patent: 5773236 (1998-06-01), Diwu et al.
patent: 5776720 (1998-07-01), Jaffe et al.
patent: 5834216 (1998-11-01), Roizman et al.
patent: 5843635 (1998-12-01), Schlossman et al.
patent: 5849513 (1998-12-01), Jaffe et al.
patent: 5871946 (1999-02-01), Lucas et al.
patent: 5897992 (1999-04-01), Fearnhead et al.
patent: 5908750 (1999-06-01), Reed et al.
patent: 5976822 (1999-11-01), Landrum et al.
patent: 6037137 (2000-03-01), Komoriya et al.
patent: 6048703 (2000-04-01), Siman et al.
patent: 6075020 (2000-06-01), Cincotta et al.
patent: 6077684 (2000-06-01), Kravtsov
patent: 6200969 (2001-03-01), Fritz et al.
patent: 6248904 (2001-06-01), Zhang et al.
patent: 6251614 (2001-06-01), Fritz et al.
patent: 6270980 (2001-08-01), Fritz et al.
patent: 6335429 (2002-01-01), Cai et al.
patent: 6342611 (2002-01-01), Weber et al.
patent: 6462041 (2002-10-01), Cai et al.
patent: 6518032 (2003-02-01), Fritz et al.
patent: 6759207 (2004-07-01), Weber et al.
patent: 6828091 (2004-12-01), Kasibhatla et al.
patent: 6984718 (2006-01-01), Zhang et al.
patent: 2002/0076733 (2002-06-01), Kasibhatla et al.
patent: 2003/0027229 (2003-02-01), Kasibhatla et al.
patent: 2003/0208037 (2003-11-01), Zhang et al.
patent: 2119840 (1994-09-01), None
patent: 0 285 179 (1988-10-01), None
patent: 0 528 487 (1993-02-01), None
patent: WO93/04192 (1993-03-01), None
patent: WO93/10461 (1993-05-01), None
patent: WO94/06906 (1994-03-01), None
patent: WO96/20721 (1996-07-01), None
patent: WO96/33209 (1996-10-01), None
patent: WO96/36729 (1996-11-01), None
patent: WO98/13517 (1998-04-01), None
patent: WO98/55863 (1998-12-01), None
patent: WO98/57664 (1998-12-01), None
patent: WO99/18856 (1999-04-01), None
patent: WO 00/04914 (2000-02-01), None
patent: WO 00/07017 (2000-02-01), None
patent: WO 00/45165 (2000-08-01), None
patent: WO 01/79187 (2001-10-01), None
patent: WO 02/12545 (2002-02-01), None
Adams, S.R., et al., “Biologically Useful Chelators That Take Up Ca2+upon Illumination,”J. Am. Chem. Soc. 111:7957-7968, American Society (1989).
Alder, A., et al., “Optical sensor for the determination of cations, its use, and fluorophores therefor,”Chemical Abstracts 123:114, The American Chemical Society, Abstract No. 35266b (1995).
Alnemri, E.S., et al., “Human ICE/CED-3 Protease Nomenclature,”Cell 87:171, Cell Press (Oct. 1996).
An, S., and Knox, K.A., “Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP,”FEBS Lett. 386:115-122, Federation of European Biochemical Societies (May 1996).
Armstrong, R.C., et al., “Fas-induced Activation of the Cell Death-related Protease CPP32 Is Inhibited by Bcl-2 and by ICE Family Protease Inhibitors,”J. Biol. Chem. 271:16850-16855, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 1996).
Assfalg-Machleidt, I., et al., “Membrane Permeable Fluorogenic Rhodamine Substrates for Selective Determination of Cathepsin L,”Biol. Chem. Hoppe-Seyler 373:433-440, Walter de Gruyter & Co. (1992).
Bonneau, P.R., et al., “Design of Fluorogenic Peptide Substrates for Human Cytomegalovirus Protease Based on Structure-Activity Relationship Studies,”Analyt. Biochem. 255:59-65, Academic Press (Jan. 1998).
Calabresi, P., and Chabner, B.A., “Chemotherapy of Neoplastic Diseases,” InGoodman&Gilman's The Pharmacological Basis of Therapeutics. Ninth Edition, The McGraw-Hill Companies, pp. 1225-1287 (Jan. 1996).
di Giovine, F.S., and Duff, G.W., “Interleukin 1: the first interleukin,”Immunol. Today 11:13-20, Elsevier Science Publishers (UK) Ltd. (1990).
Dilanni, C.L., et al., “In Vitro Activity of the Herpes Simplex Virus Type 1 Protease with Peptide Substrates,”J. Biol. Chem. 268:25449-25454, The American Society for Biochemistry and Molecular Biology, Inc. (1993).
Dinarello, C.A., “Interleukin-1 and Interleukin-1 Antagonism,”Blood 77:1627-1652, W. B. Saunders Company (1991).
Ding, J., et al., “Crystal structure of the human adenovirus proteinase with its 11 amino acid cofactor,”EMBO J. 15:1778-1783, IRL Press Limited (Apr. 1996).
Diouri, M., et al., “Cleavage Efficiency by Adenovirus Protease Is Site-dependent,”J. Biol. Chem. 271:32511-32514, The American Society for Biochemistry and Molecular Biology, Inc. (Dec. 1996).
Evans, D.B., et al., “An Ultrasensitive Human Immunodeficiency Virus Type 1 Protease Radioimmuno Rate Assay with a Potential for Monitoring Blood Levels of Protease Inhibitors in Acquired Immunodeficiency Disease Syndrome Patients,”Analyt. Biochem. 206:288-292, Academic Press, Inc. (1992).
Evan, G., and Littlewood, T., “A Matter of Life and Cell Death,”Science 281:1317-1322, American Association for the Advancement of Science (Aug. 1998).
Friesen, C., et al., “Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nature Med. 2:574-577, Nature Publishing Group (May 1996).
Fulda, S. et al., “Betulinic Acid Triggers CD95 (APO-1/Fas)- and p53-independent Apoptosis via Activation of Caspases in Neuroectodermal Tumors,”Cancer Res. 57:4956-4964, American Association of Cancer Research (Nov. 1997).
Gamen, S. et al., “Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way,”FEBS Lett. 417:360-364, Elsevier Science Publishers B.V. (Nov. 1997).
Ganesh, S., et al., “Flow Cytometric Determination of Aminopeptidase Activities in Viable Cells Using Flurorgenic Rhodamine 110 Substrates,”Cytmetry 20:334-340, Wiley-Liss, Inc. (1995).
Gallop, M.A., et al., “Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries,”J. Med. Chem. 37:1233-1251, American Chemical Society (1994).
Gao, M., et al., “The Protease of Herpes Simplex Virus Type 1 Is Essential for Functional Capsid Formation and Viral Growth,”J. Virol. 68:3702-3712, American Society for Microbiology (1994).
Gordon, E.M., et al., “

Affiliated with

Also associated with

Rating

Fluorogenic or fluorescent reporter molecules and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fluorogenic or fluorescent reporter molecules and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorogenic or fluorescent reporter molecules and their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3782446